88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"? BEIJING , Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy NANJING, China , Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026 SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth SHANGHAI , Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
/C O R R E C T I O N -- Akeso, Inc./ In the news release, Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline, issued 21-Aug-2026 by Akeso, Inc. over PR Newswire, we are ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Sunshine Guojian Releases 2026 Interim Report: Innovation-driven, Steady Advancement ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 ... 2026-08-21T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Angel Yeast's AHH Packaging Design Recognized with Red Dot Award SHANGHAI , Aug. 20, 2026 /PRNewswire/ -- Angel Nutritech, a professional yeast biotechnology subsidiary under Angel Yeast (SSE: 600298), has been recognized for its Angel Human Health (AHH) yeast essence ... 2026-08-21T Biotechnology Food/Beverages Health Care/Hospital
Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints ... 2026-08-20T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved